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ecades of basic and clinical neuroscience
research have greatly improved our understanding of the
neurobiology of depression.Clinical studies have helped
establish which treatments are effective,and have led to
evidence-based treatment algorithms that can be readily
applied to the “real-world”situation.
1 Basic research has
yielded insights into the genetic,molecular,cellular,and
neuroanatomical bases of depression. Based on these
findings,there is a growing acceptance of depression,and
other mood disorders,as diseases of the brain rather than
purely aberrations of “mind.”
Despite these advances, depression remains a common
and inadequately treated illness, with few strategies for
prevention or cure.The lifetime prevalence of depres-
sion approaches 17% in the United States,
2 and depres-
sion is recognized to be one of the leading causes of 
disability worldwide.
3,4Available treatments for depres-
sion—including pharmacotherapy, evidence-based psy-
chotherapy, and electroconvulsive therapy (ECT)—are
effective in reducing symptoms in the majority of
patients with an acute depressive episode,and the com-
bination of these treatments may be more efficacious
than individual treatments alone.
5 However, up to 40%
of patients continue to have clinically significant symp-
toms despite optimized treatment,
6 and up to 20% of
patients may show little to no response to the most
aggressive management (including the use of ECT).
7-9
Even for patients who do respond to treatment, the ill-
ness tends to be highly recurrent, with up to 80% of
patients experiencing at least one subsequent episode.
10
Psychotherapy and/or maintenance antidepressant med-
ications may substantially decrease the risk of relapse
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Major depression is a common, disabling, and often dif-
ficult-to-treat illness. Decades of research into the neu-
robiology and treatment of depression have greatly
advanced our ability to manage this disorder. However,
a number of challenges remain. A substantial number of
depressed patients do not achieve full remission despite
optimized treatment. For patients who do achieve reso-
lution of symptoms, depression remains a highly recur-
rent illness, and repeated episodes are common. Finally,
little is known about how depression might be pre-
vented, especially in individuals at increased risk. In the
face of these challenges, a number of exciting research
efforts are currently under way and promise to greatly
expand our knowledge of the etiology, pathophysiology,
and treatment of depression. This review highlights
these future prospects for depression research with a
specific focus on lines of investigation likely to generate
novel, more effective treatment options.     
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In the face of these clear challenges,the continued neu-
robiological investigation of depression offers reason for
optimism. Based on a solid foundation, basic and clini-
cal neuroscience research is progressing rapidly, with
many exciting developments on the horizon.
Importantly, as the pathophysiology of depression
becomes better understood, a number of novel treat-
ment targets are being identified. These treatments
promise to offer unique mechanisms of action that will
likely allow clinicians to improve on the current rates of
response and remission.Further,as the factors that con-
tribute to the development of depression are better
described, there is hope that effective preventive and
curative strategies may eventually be developed,as well
as predictors of response to one treatment versus
another being identified.
In this review, we discuss a number of these exciting
potential directions for future research in depression.
We begin with a review of the role of monoamine cir-
cuit dysfunction in depression and describe some
avenues for further research on these neurotransmitter
systems.We then discuss the putative role of neuroen-
docrine and neuropeptide systems and some novel
treatment strategies involving these systems.A number
of other neuromodulatory systems are then reviewed
briefly, again with a focus on novel drug development.
We conclude with a discussion of the neuroanatomical
basis and neural network theories of depression,
emphasizing recent developments in neuroimaging and
focal brain stimulation.
Monoamine neurotransmitter systems
Monoamine deficiency is among the oldest of the neu-
rochemical theories of depression,
12,13 with much research
over the last four decades focused on monoaminergic
function.The monoamine neurotransmitter systems—
including serotonin,norepinephrine (NE),and dopamine
—are widely distributed throughout the central nervous
system and are involved in the regulation of many
aspects of behavior including mood,cognition,locomo-
tion,sleep,appetite,libido,arousal,anxiety,and aggres-
sion.The monoamine systems largely function as mod-
ulators of excitatory and inhibitory neurotransmitter
circuits.Although each neurotransmitter system appears
to regulate a distinct cluster of functions, considerable
overlap exists between these systems.Each is reviewed
below.
Serotonin
Serotonin (5-HT) is produced in cells of the rostral and
caudal raphe nuclei.Serotonergic projections are wide-
spread throughout the central nervous system (CNS) and
include several brain regions implicated in the patho-
physiology of depression,including the hypothalamus,
thalamus, hippocampus, amygdala, basal ganglia, pre-
frontal cortex,and cingulate cortex.The effects of sero-
tonin are mediated through pre- and postsynaptic 5-HT
receptors;to date,at least 13 molecular subtypes of 5-HT
receptors have been identified.Among these subtypes,
three major families of receptors have been linked to
depression:5-HT1a/b,5-HT2a/c,and 5-HT3.After release
from the presynaptic nerve terminal,5-HT binds to 5-HT
receptors or is taken up into the presynaptic terminal by
the serotonin transporter (SERT) and either repackaged
into a terminal vesicle or catabolized by monoamine oxi-
dase (MAO).
Serotonergic dysfunction has been clearly and consis-
tently linked with most,if not all,forms of depression.
14
Cerebrospinal fluid (CSF) levels of serotonin metabo-
lites—primarily 5-hydroxyindole acetic acid (5-HIAA)—
are generally reduced in depressed patients
15 and are
even lower in depressed patients with a history of suicide
attempts.
16Tryptophan depletion can lead to a depressive
relapse in euthymic patients with a history of depression
responsive to selective serotonin reuptake inhibitors
(SSRIs).
17,18 SERT availability has been shown to be
reduced in several brain regions in patients with major
Basic research
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Selected abbreviations and acronyms
5-HT serotonin
CNS central nervous system
CRF corticotropin-releasing factor
CSF cerebrospinal fluid
DA dopamine
DBS deep brain stimulation
ECT electroconvulsive therapy
GABA γ-aminobutyric acid
HPA axis hypothalamic-pituitary-adrenal axis
HPT axis hypothalamic-pituitary-thyroid axis
NE norepinephrine
SERT serotonin transporter
SSRI selective serotonin reuptake inhibitor
TMS transcranial magnetic stimulation
VNS vagus nerve stimulationdepression,
19-21 though discordant findings have
appeared.
22Abnormalities in SERT binding have been
consistently identified in depression.
23 Of paramount
importance,all SSRIs are efficacious in the treatment of
depression,and are generally considered first-line treat-
ment for the illness.
Many of the effects of serotonin on mood and behavior
are thought to be mediated through action at postsynap-
tic 5-HT2 receptors.
24 In unmedicated suicide victims with
depression,an increased density of 5-HT2 receptors has
been reported in the prefrontal cortex and amygdala,
25
and, similar to findings with SERT, in platelets.
26
Treatment with antidepressant medications is generally
associated with decreased density of 5-HT2 receptors
over a time course that corresponds to the onset of anti-
depressant efficacy—this finding suggests that upregula-
tion of 5-HT2 receptors in depression may be a compen-
satory response to a chronically low serotonergic state.
However,other data suggest that 5-HT2 receptor activ-
ity may not completely normalize with antidepressant
treatment.
27Also,using a radiolabled positron emission
tomography (PET) ligand for the 5-HT2 receptor,Biver
et al
28 found reduced 5-HT2 activity in the right
orbitofrontal and insular cortices.Another group found
no difference in 5-HT2 activity in depressed patients ver-
sus normal controls
29;however,this study excluded sub-
jects with suicidal ideation.
Depression is a highly heritable illness,with one third of
the risk for developing the disorder explained by genetic
factors and two thirds of the risk attributable to the envi-
ronment.A growing database suggests that the relation-
ship of serotonin function and depression may be mod-
ulated in part by a gene-environment interaction. An
early study showed an association between depression
and a functional polymorphism of the promoter region
for the SERT gene (5-HTTLPR).
30The 5-HTTLPR has
two alleles:a “short”(s) version and a “long”(l) version;
presence of an s allele is associated with a functionally
significant decrease in SERT activity.Other studies have
shown an association between the presence of the s allele
and the personality trait of neuroticism.
31 A landmark
study demonstrated that the 5-HTTLPR polymorphism
moderated the influence of stressful life events on the
development of depression.
32 Specifically, this study
showed that individuals homo- or heterozygous for the s
allele were more likely to develop depressive syndromes
after exposure to childhood abuse or neglect compared
with subjects homozygous for the l allele.At least two
large-scale studies have replicated this finding,
33,34
although not all studies are consistent.
35,36 Some studies
have suggested this gene-environment interaction may
be stronger in females than males.
35,37
Norepinephrine
Norepinephrine (NE) is primarily produced in cells of
the pontine locus ceruleus. Similar to 5-HT neurons,
these cells project to multiple cortical and subcortical
brain regions,many of which have been implicated in the
biology of depression.The NE system is well known to
modulate the stress response, and the locus ceruleus
receives inputs from several other neurotransmitter sys-
tems providing information about homeostasis (eg,5-HT,
opioids, γ-aminobutyric acid (GABA), corticotropin-
releasing factor (CRF), DA, and glutamate).
Norepinephrine exerts its effects through interaction
with pre- and postsynaptic α- and β-adrenergic receptors.
Similarly to 5-HT,following release from the presynap-
tic nerve terminal,NE is taken back up into the presy-
naptic terminal by the norepinephrine transporter (NET)
where it is either repackaged or metabolized by MAO.
A role for NE in the pathophysiology of depression is
fairly well-established but less clear than for 5-HT.
Administration of drugs that deplete NE stores (such as
reserpine) can precipitate depressive symptoms—how-
ever,such drugs affect stores of other neurotransmitters
such as 5-HT and DA.Studies of NE metabolite levels
(primarily 3-methoxy-4-hydroxy-phenylglycol [MHPG])
in the CSF of depressed patients have yielded inconsis-
tent results.Currently,radioligands for the majority of
NE receptors and the NET are not available for use in
humans.However,depletion of NE in depressed patients
taking noradrenergic antidepressants can result in
depressive relapse.
38 Further, depleting NE (as well as
DA) in euthymic,unmedicated patients with a history of
depression can precipitate a relapse.
39 Suicide victims
have been reported to exhibit increased activity of tyro-
sine hydroxylase,the enzyme that controls the rate-lim-
iting step of synthesis of NE in the locus ceruleus.
40 Drug-
free depressed patients exhibit a blunted growth
hormone response to clonidine,an α2-adrenergic agonist.
A role for the NE system in depression is further sup-
ported by data on the effects of antidepressant medica-
tions in humans and animal models.Selective NE reup-
take inhibitors (eg, maprotiline, desipramine, and
reboxetine) have all been shown to be efficacious in the
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177treatment of depression.Many tricyclic antidepressant
(TCA) medications inhibit both NE and 5-HT uptake,
including imipramine.So-called non-TCA “dual”reup-
take inhibitors, such as duloxetine and venlafaxine,
inhibit reuptake of both 5-HT and NE,are effective in
treating depression,and have been suggested to be more
efficacious overall than certain SSRIs,
41,42 though this
remains a controversial area.Chronic administration of
antidepressant medications or electroconvulsive shock
(ECS) are associated with increased noradrenergic neu-
rotransmission.
43-48
Dopamine
Dopamine (DA) neurotransmission is primarily orga-
nized into three distinct systems within the brain:(i) the
nigrostriatal pathway in which DA is produced in the A9
cells of the substantia nigra with projections to the dor-
sal basal ganglia;(ii) the mesolimbic-mesocortical path-
way in which DA is produced in A10 cells in the ventral
tegmental area (VTA) of the midbrain with projections
to the ventral striatum,other limbic regions (mesolimbic
pathway) and prefrontal cortex (mesocortical pathway);
and (iii) the tuberoinfundibular pathway in which DA is
produced in A12 cells of the arcuate nucleus of the hypo-
thalamus with projections to the intermediate and neural
lobes of the pituitary.Three other DA systems have also
been described
49:(i) a periventricular system arising from
the dorsal motor vagus nuclei, nucleus of the solitary
tract,periaqueductal and periventricular gray,and pro-
jecting to midbrain structures including tegmentum,tec-
tum,thalamus,and hypothalamus;(ii) an olfactory bulb
system arising from the periglomerular cells in the olfac-
tory bulb;and (iii) an incertohypothalamic circuit from
the zona incerta to the hypothalamus.
DA exerts effects at DA receptors,of which several sub-
types have been identified, and, similarly to 5-HT and
NE,DA is taken up into the presynaptic terminal via a
DA transporter (DAT).Interestingly,DA nerve termi-
nals in the prefrontal cortex of humans and other pri-
mates contain no DAT,and the DA signal is inactivated
by uptake into nearby NE nerve terminals by NET.For
this reason,NE reuptake inhibitors increase DA avail-
ability in the prefrontal cortex.Along with 5-HT and NE,
DA is catabolized by MAO.
DA is a precursor for NE,but its role in depression has
been far less scrutinized. CSF concentrations 
of the major metabolite of DA—homovanillic acid
(HVA)—are decreased in depressed patients,
50,51 and
urine levels of 3,4-dihydroxyphenylacetic acid (DOPAC;
another metabolite of DA) have been shown to be
decreased in depressed patients
52 and potentially associ-
ated with suicidal behavior.
50There is evidence from both
brain imaging studies of the DAT
53 and postmortem stud-
ies
54 that DA neurons are reduced in activity in depres-
sion.Depression is highly comorbid with Parkinson’s dis-
ease, which is characterized by loss of DA cells in the
substantia nigra and VTA;however,it should be noted
that 5-HT and NE systems are also disrupted in
Parkinson’s disease.
55-57 Monoamine oxidase inhibitors
(MAOIs),which have demonstrated efficacy in treating
depression, decrease catabolism of all monoamines
including DA.Certain medications that primarily affect
the DA system,such as psychostimulants and pramipex-
ole,also have antidepressant efficacy,
58-60 particularly in
bipolar depression.
Future directions for monoamine systems research
The monoamine deficiency hypothesis of depression has
remained dominant for many years.However,treatments
based solely on this hypothesis have proven to be only
moderately effective. As the neurobiological under-
standing of depression matures, it is increasingly clear
that a “simple”monoamine hypothesis of depression is
inadequate.
Future research will help clarify the role of the
monoamines in depression within the context of a larger
genetic-neurochemical-neuroanatomical-environmental
framework.Although discussed separately,it should be
recognized that the 5-HT,NE,and DA systems interact
to modulate neural function.For example,5-HT neurons
have synapses on locus ceruleus cells and NE neurons
innervate cells in the raphe nuclei.Further,it is clear that
the monoamines operate within a larger neurochemical-
neuroanatomical system. As discussed below, several
brain regions have been implicated in depression,includ-
ing the hippocampus. In animal models, chronic treat-
ment with antidepressants increases the rate of neuro-
genesis within the hippocampus,
61 suggesting that
site-specific action of these medications may be impor-
tant. Gene-environment studies suggest that genetic
determinants of monoamine function such as SERT
polymorphisms determine the degree to which environ-
mental stressors affect one’s vulnerability to depression.
Future studies of the monoamines in depression will
Basic research
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interactions within the monoamine systems will help
clarify the specific role of each system in the patho-
physiology of depression. Prior studies suggest that
some patients respond well to medications that selec-
tively modulate 5-HT function,others respond to med-
ications that affect 5-HT and NE function, while still
others appear to require modulation of all three
monoamine systems (eg,via MAOIs).Several pharma-
ceutical companies are developing “triple” reuptake
inhibitors which inhibit reuptake of all three
monoamines.
62,63 Studies exploring the interactions
between the monoamine systems and other neuro-
transmitter/neuromodulatory systems (eg, CRF, neu-
rokinins, glutamate, and GABA—discussed in more
detail below) will help develop realistic,integrated neu-
rochemical models of depression. Functional imaging
studies combined with neurochemical challenge will
help clarify the anatomical specificity of monoaminer-
gic dysfunction in depression. For example, PET imag-
ing can be combined with monoamine depletion strate-
gies to investigate the functional neuroanatomy of
depressive relapse with decreased monoamines.
64-66
Development of radioligands for various monoamine
receptors and transporters will help identify in which
brain regions and to what degree these systems are
abnormal in patients with depression. Genetic studies
will also be more informative by incorporating imaging
approaches.To date,at least two studies have suggested
that 5-HTTLPR polymorphisms affect the structure,
function, and functional connectivity of brain regions
implicated in the pathophysiology of depresson.
67,68
Recently,we reported that NET polymorphisms predict
response to milnacipran, a dual 5-HT/NE reuptake
inhibitor, but not fluvoxamine, an SSRI.
69 Future stud-
ies will help identify whether this has potential etiologic
meaning in depression; also, it is likely that other
genetic variations will be identified and investigated in
similar fashion.
Neuroendocrine systems
The potential contribution of dysfunction of the
endocrine system to the neurobiology of depression has
long been recognized.Most research has focused on the
hypothalamic-pituitary-adrenal (HPA) axis and, to a
lesser degree, on the hypothalamic-pituitary-thyroid
(HPT) axis.
HPA axis
In vulnerable individuals,psychological and physiologi-
cal stress has long been known to precipitate or worsen
depressive episodes.The HPA axis is the primary neu-
roendocrine system responsible for coordinating the
mammalian stress response,and has thus been a major
focus of research into the neurobiology of depression.Its
major components include corticotropin-releasing factor
(CRF),adrenocorticotropin hormone (ACTH) and glu-
cocorticoids; cortisol is the major glucocorticoid in
humans.During the stress response,neurons in the par-
aventricular nucleus (PVN) of the hypothalamus release
CRF into the hypothalamo-hypophysial portal system.
CRF then stimulates adrenocorticotropin (ACTH)
release from the anterior pituitary into the systemic cir-
culation,which in turn stimulates the adrenal cortex to
secrete cortisol.Cortisol is responsible for many of the
physiological changes associated with the stress response,
and also provides negative feedback to the hypothalamus
and pituitary to decrease synthesis and release of CRF
and ACTH.
Quite distinct from the HPA axis is the widespread CNS
distribution of CRF and CRF receptors that includes sev-
eral cortical, subcortical, and brain stem regions.
Importantly, these CRF systems modulate the auto-
nomic,immunologic,and behavioral responses to stress.
70
Two main CRF receptor subtypes have been identified
(CRF1 and CRF2) which appear to have differential
effects on behaviors related to mood and anxiety.CRF1
receptors have a high affinity for CRF, and are widely
distributed in the CNS, and reduced anxiety in animal
models is associated with reduced activity of these recep-
tors.In contrast,CRF2 receptors have a lower affinity for
CRF,have a widespread distribution with limited over-
lap with that of CRF1 receptors,and reduced CRF2 activ-
ity has been linked with increased anxiety-like behaviors
in animals.
70,71
The HPA axis is abnormally active in patients with
depression. CSF CRF concentrations are elevated in
drug-free depressed patients compared with controls,and
CRF mRNA expression and the number of CRF-con-
taining neurons in the PVN are increased in depressed
patients.
72,73 CRF concentrations are elevated in the
frontal cortex of depressed patients,and there is a corre-
sponding reduction in CRF1 receptors in suicide victims
in this area.
74,75 Further, antidepressants modify CRF
activity. In a group of healthy volunteers, desipramine
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was shown to decrease CSF CRF concentrations,
76 and
both fluoxetine and ECT have been reported to produce
similar changes in depressed patients.
77These data point
to a potentially critical role for CRF in the pathophysi-
ology of depression.
Some data suggest that particular subtypes of depression
may be associated with unique HPA axis abnormalities.
Patients with psychotic depression demonstrate signifi-
cant HPA axis hyperactivity and show the highest rates
of HPA axis nonsuppression during the dexamethasone
suppression test (DST).
78 Conversely, patients with
nonpsychotic depression may demonstrate evidence of
decreased or normal HPA axis activity.
79 Depressed
patients with a history of early life stress show elevated
plasma ACTH and cortisol concentrations in response to
a laboratory stressor,whereas depression patients with-
out such a history do not.
80 In one large treatment study
of chronic depression, subjects with a history of child-
hood trauma responded preferentially to a form of cog-
nitive-behavior therapy (CBT) over pharmacotherapy
with the antidepressant nefazodone,suggesting that sub-
types of depression related to altered stress response may
have important treatment implications.
81
In view of these findings, considerable interest has
focused on developing novel antidepressant medications
that target the HPA axis directly,and this promises to be
an exciting direction for future research in depression.To
date,selective CRF1 receptor antagonists have received
the most attention, though CRF2 agonists might offer
another useful target. Several CRF1 antagonists are in
various stages of development (see Gutman et al
70 for a
review).The effects of only one agent, R121919, have
been published.
82Although this agent showed evidence
of antidepressant and anxiolytic activity in depressed
patients,
82 liver toxicity has eliminated it as a viable novel
drug candidate.Current and future studies will assess the
antidepressant properties of a variety of CRF1 and pos-
sibly CRF2 antagonists.
Other antidepressant treatment strategies based on HPA
axis modulation include glucocorticoid synthesis
inhibitors and glucocorticoid receptor blockade.Drugs
that interfere with cortisol synthesis (eg,ketaconozale,
aminoglutethimide,and metyrapone) have potential anti-
depressant effects; however, data are limited and the
unfavorable side effects of these agents limit their poten-
tial utility.
83 The glucocorticoid receptor antagonist
mifepristone (RU486)—a selective type II glucocorticoid
receptor antagonist—has shown modest antidepressant
effects in chronic depression,
84 and encouraging effects in
the treatment of psychotic depression.
85,86 Of interest,the
positive effects of mifepristone were demonstrated
within 1 week of treatment,and the greatest effects were
on the psychotic symptoms, not the core symptoms of
depression.Given the high rate of HPA axis hyperactiv-
ity in psychotic versus nonpsychotic depression,this sug-
gests an important potential mechanism of action specific
to psychosis in depression.
Future studies in depression will further explore these
findings,and promise to add an important group of med-
ications to the treatment repertoire for depression.
Beyond this,research is currently under way to delineate
the epidemiological,biochemical,and genetic factors that
mediate the effects of psychosocial stress on depressive
syndromes.An important aspect of this research will be
to better define the interaction between the HPA axis
and the monoamine neurotransmitter systems,especially
given the apparent role of serotonin neurotransmission
in modulating the effects of stress on the development of
depression (see above). For example, we recently
reported that 5-HT depletion in humans is associated
with dramatic increases in CSF CRF concentrations,
demonstrating an important 5-HT-CRF link.
87
HPT axis
Hypothyroidism is classically associated with a depres-
sive syndrome that is ameliorated by correcting the
underlying thyroid hormone deficit.This suggests a rela-
tion between the hypothalamic-pituitary-thyroid (HPT)
axis and the neurobiology of depression.In the HPT axis,
thyrotropin-releasing hormone (TRH) is secreted by the
hypothalamus and stimulates thyroid-stimulating hor-
mone (TSH) release from the pituitary.TSH acts on the
thyroid to stimulate iodine uptake,follicle cell metabo-
lism, and release of the two thyroid hormones (tri-
iodothyronine [T3] and thyroxine [T4]). Thyroid hor-
mones are responsible for a number of homeostatic and
metabolic functions and also provide feedback to the
hypothalamus and pituitary to decrease further TRH and
TSH release,respectively.
A mixed database supports some role for the HPT axis
in the pathophysiology of depression. In depressed
patients,CSF TRH has been shown to be elevated (sug-
gesting decreased feedback from thyroid hormones)
compared with controls,
88,89 though discordant findings
have been reported.
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blunted TSH response to TRH stimulation in depressed
patients despite normal thyroid hormone levels,
91 consis-
tent with downregulation of TRH receptors in the pitu-
itary, perhaps secondary to elevated TRH levels.
Alternatively,thyroid hormone in the periphery may not
be efficiently transported into the CNS in depressed
patients;CSF levels of transthyretin—the protein respon-
sible for transporting thyroid hormones across the blood-
brain barrier at the choroid plexus—have been shown to
be decreased in depressed patients.
92,93Thyroid hormone
augmentation (primarily with T3) has been reported to
exert antidepressant effects,even in the absence of clin-
ical hypothyroidism,
94-95 though several negative studies
are available (P.Ninan and C.B.Nemeroff,unpublished
observations).
96
Future studies will help clarify the role of the HPT axis
in the pathophysiology and treatment of depression.As
with the HPA axis,areas of interest include the interac-
tion of the HPT system with other neuromodulatory sys-
tems. Of particular interest is whether patients with 
subclinical hypothyroidism, such as symptomless
autoimmune thyroiditis, or particular subtypes of
depression are more likely to respond to thyroid aug-
mentation.
Other neuromodulatory systems
In addition to the monoamines and constituents of the
neuroendocrine systems, there are a number of other
neuromodulators that have been implicated in the neu-
robiology of depression.Increasing research efforts have
focused on these systems,especially as potential targets
for novel drug development. In general, future studies
will help clarify the role of these systems in the patho-
physiology and treatment of depression. In particular,
the relation between these systems and other neuro-
transmitter systems will need to be better delineated.
Also, given the general lack of anatomic specificity for
some of these systems (such as glutamate and GABA),
drug development will need to focus on agents that
show potential antidepressant efficacy without addi-
tional unwanted adverse effects.A promising new direc-
tion in pharmacological research involves the system
implicated in circadian rhythms. Agomelatine, which
acts as an agonist at melatonin MT1/MT2 receptors and
an antagonist at 5HT2c receptors,has proven its antide-
pressant efficacy in clinical trials,
97 and has a favorable
tolerability profile.
Glutamate
Glutamate is the primary excitatory neurotransmitter in
the brain. Glutamate receptors are divided into two
types: ionotropic (including the N-methyl-D-aspartate
[NMDA],α-amino-3-hydroxy-5-methyl-4-isoxazide pro-
pionic acid [AMPA], and kainite receptors) and
metabotropic (including a family of G-protein coupled
receptors associated with adenyl cyclase and phospho-
inositide second messenger systems).Excitatory gluta-
matergic neurotransmission likely plays a role in depres-
sion.
98,99 Indeed,stress may contribute to depression by
increasing excitatory glutamatergic neurotoxicity in brain
areas involved in mood regulation. Sanacora et al
reported that depressed patients had higher cortical glu-
tamate levels compared with healthy controls,using mag-
netic resonance spectroscopy.
100
Ionotropic glutamate receptor antagonists can decrease
stress-induced loss of hippocampal neurons,
101,102 and data
suggest amantadine (a nonselective NMDA receptor
antagonist) may enhance antidepressant-like effects of typ-
ical antidepressants in animal models
103,104 and depressed
patients.
105 Preclinical studies of selective NMDA receptor
antagonists have revealed antidepressant-like effects in
animal models.
106,107 Additionally, agents that enhance
AMPA receptor function may augment antidepressant
effects of standard antidepressant medications.
108 Riluzole,
which inhibits glutamate release,has shown preliminary
antidepressant effects in patients with bipolar depres-
sion,
109,110 but no placebo-controlled data are available and
effects in unipolar depression have not been studied.
GABA
GABA is the major inhibitory neurotransmitter in the
CNS. There are two major types of GABA receptors:
GABAa and GABAb. GABAa receptors are chloride
channels and contain the binding site for benzodiazepines.
GABAb receptors are coupled to calcium channels.A role
for GABA in the pathophysiology of depression has long
been postulated,and several recent studies support this
hypothesis.
111,112 Preclinical studies have demonstrated
decreased CNS GABA concentrations in animal models
of depression.
111 CSF and plasma GABA concentrations
have been reported to be decreased in depressed
patients.
111 Postmortem investigation of the hippocampus
in depressed patients suggested possible GABAergic dys-
function.
113 GABAb receptors are found on most 5-HT-containing neurons in the dorsal raphe, and GABA
release into the dorsal raphe decreases firing of 5-HT neu-
rons.
114 Modulating GABAb function has been shown to
have important behavioral effects in animal models,with
GABAb antagonists demonstrating certain antidepressant-
like properties.
112,114 Using magnetic resonance spec-
troscopy,Sanacora et al demonstrated decreased GABA
concentrations in the occipital cortex of depressed
patients.
100,115 Moreover, this group showed GABA con-
centrations increase in the occipital cortex after SSRI
treatment and ECT,
116,117 but not after CBT.
118 CNS GABA
concentrations have also been shown to be normal in
remitted depressed patients compared with controls.
119
Neurokinins
Neurokinins are neuropeptides widely distributed in the
CNS and peripheral nervous system,and are believed to
play a role in nociception.Substance P is the most abundant
neurokinin in humans and is found in neurons in several
brain regions implicated in the neurobiology of depres-
sion.
120 Substance P is also colocalized in cells containing 5-
HT and NE.
121-124 Substance P binds to several receptor sub-
types (NK-1, NK-2, NK-3, NKA, NKB), and appears to
have an important role in modulating the mammalian stress
response.In animal models,substance P results in behav-
ioral and physiologic changes characteristics of a stress
response.
125,126These changes can be attenuated by substance
P antagonists.
127,128 Supporting its role in depression,CSF
substance P concentrations were reported to be elevated in
depressed patients compared with controls,
129-131 and lower
serum concentrations of substance P have been correlated
with better antidepressant treatment response.
130 Our group
has reported elevations in CSF substance P concentrations
in drug-free patients with major depression and PTSD.
132
One placebo-controlled study using a neurokinin receptor
(NK-1) antagonist (MK-869) suggested efficacy in treating
depression,
127 but several follow-up studies found no signif-
icant antidepressant effects for this agent.
133Two other selec-
tive NK-1 receptor antagonists (L-759274 and CP-122721)
have shown potential efficacy in treating depression,
134,135
although data are relatively limited.In general,these drugs
appear to be well-tolerated.
Neuroanatomical models
Several lines of evidence support a neuroanatomical
basis for depression. Brain regions consistently impli-
cated in the neurobiology of mood regulation and
depression include the prefrontal cortex (including dor-
solateral,ventromedial,and orbitofrontal portions),cin-
gulate cortex (primarily the ventral anterior cingulate
and subgenual cingulate), thalamus, amygdala, hip-
pocampus,ventral striatum,portions of the temporal and
parietal cortices, and various midbrain and brain stem
nuclei.The data supporting a role for these brain regions
in depression has been extensively reviewed elsewhere,
136-141
and primarily include studies of depression in neurolog-
ical disease (such as Parkinson’s disease,Huntington’s
disease,Alzheimer’s dementia,and traumatic brain injury
including stroke),neuropathological studies in depressed
patients, and neuroimaging studies. On a histological
level, evidence suggests a number of microstructural
abnormalities in depression,including defects in neuronal
and glial cell structure and white matter integrity.
140,142
As data have accumulated,increasingly complex models
of mood regulation have been developed.
136,137,139,143,144
These models are largely based on the premise that
widely distributed brain regions are structurally and func-
tionally connected such that their coordinated activity is
required for normal mood regulation.Thus,there is less
emphasis on the function of a specific brain region in iso-
lation, and more weight given to how multiple brain
regions function together.Depression,and other mood
disorders,are then characterized by network dysfunction
(ie, abnormalities in the coordination of two or more
brain regions).
Neural network models of depression form the basis for
several exciting directions for future mood disorders
research.It is expected that neuroimaging methods will
continue to become more sophisticated and better
describe the structure and function of the brain in
depressed patients at various stages in the illness (eg,
prior to treatment, in remission, or during treatment
resistance).Novel uses of neuroimaging (many of which
have been mentioned in previous sections) include recep-
tor/transporter imaging,combined pharmacology-imag-
ing studies,neurochemical challenge studies,and func-
tional imaging studies (both resting state and
task-activated).Diffusion tensor imaging (DTI) provides
information on the integrity of white matter tracts and
can be used for tractography
145; such studies may help
correlate abnormalities in functional connectivity in
depression with abnormalities in structural connectivity.
Combination of imaging with other research methods
(eg,genetic,neuroendocrine,and focal brain stimulation
Basic research
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[discussed below]) may eventually help provide detailed
multifactorial “profiles”of depressive subtypes.
Another research direction that has both developed out
of,and contributed to,neural network theories of depres-
sion is focal brain stimulation. Focal brain stimulation
techniques (including transcranial magnetic stimulation
[TMS], vagus nerve stimulation [VNS] and deep brain
stimulation [DBS]) are designed to provide direct,mod-
ifiable stimulation to a specific brain region with the goal
of modulating function throughout a particular neural
system.* Over the last several years, these techniques
have been used increasingly to study the neurobiology of
depression and as potential antidepressant therapies.
Transcranial magnetic stimulation
Transcranial magnetic stimulation (TMS) uses a current
passed through an electromagnetic coil on the scalp to
create a brief,rapidly changing magnetic field.This mag-
netic field experiences little to no impedance from the
scalp, skull and air, and is able to induce a small, focal
electrical current within the underlying cortex,resulting
in depolarization of cortical neurons.Although single-
pulse TMS is an established diagnostic and research tool
in humans,
146 repetitive TMS (rTMS) has been most
extensively studied as a possible treatment for depres-
sion. By convention, high-frequency or “fast” rTMS
refers to stimulation delivered at a rate higher than 1 Hz,
and low-frequency or “slow”rTMS refers to stimulation
at frequencies of 1 Hz or slower.No anesthesia is needed
when giving rTMS (except in the case of magnetic
seizure therapy [MST] discussed separately below).
rTMS has been associated with behavioral changes in
animals similar to those achieved with electroconvulsive
shock and suggestive of an antidepressant effect,
147,148 and
functional imaging studies have confirmed that TMS can
modulate function in several brain regions (including
subcortical structures) implicated in mood regulation.
149,150
Several studies have shown antidepressant effects for fast
rTMS applied to the left dorsolateral prefrontal cor-
tex
151,152;a smaller number have shown efficacy for slow
rTMS applied to the right dorsolateral prefrontal cor-
tex.
153,154Although meta-analyses of these studies gener-
ally agree that rTMS appears to have statistically signif-
icant antidepressant effects,the clinical significance of
these effects has yet to be convincingly demonstrated.
155
rTMS appears to be safe and reasonably well-tolerated.
Magnetic seizure therapy (MST) uses a modified rTMS
system to induce a generalized seizure similar to that
obtained with ECT.The goal is obtain the same efficacy
as with more focal forms of ECT (eg,right unilateral lead
placement) but with fewer cognitive side effects.Indeed,
there is some preliminary data to support an antidepres-
sant effect for MST with fewer cognitive side effects com-
pared with ECT,
156,157 but confirmatory data are lacking.
Future studies will help clarify whether TMS offers a clin-
ically useful treatment alternative in depression.
However,even if TMS proves to be ineffective as an anti-
depressant treatment,it will likely continue to be useful
as a probe of neural function,especially when combined
with neuroimaging.
158When combined with imaging of
regional blood flow or glucose metabolism,TMS can be
used to better define the degree of functional connectiv-
ity between brain regions involved in mood regulation.
159
Combined with neurochemical imaging (such as recep-
tor imaging),TMS can be used to probe the role of spe-
cific neurotransmitter systems.
150
Vagus nerve stimulation
Vagus nerve stimulation (VNS) uses a programmable
electrical stimulator to provide intermittent stimulation
to a patient’s left vagus nerve.VNS was originally FDA-
approved for treatment-resistant epilepsy
160 and was
recently approved for the adjunctive treatment of a
major depressive episode that has not responded to at
least four antidepressant medication trials.However,the
efficacy data on VNS are mixed. Mood improvements
have been reported by epileptic patients receiving VNS,
161
and one open and one double-blind study have shown
antidepressant efficacy for VNS in depressed epilepsy
patients.
162,163A single open study of VNS in 60 nonepilep-
tic patients with treatment-resistant depression found a
31% response rate and 15% remission rate after 10
weeks
164; response and remission were generally main-
tained after at least 1 year of treatment
165 and showed fur-
ther increases after 2 years of treatment.
166 However,a
large,sham-controlled study failed to show statistically
significant antidepressant effects for active VNS
167 after
10 weeks of treatment.After 1 year of active VNS (all
sham-treated patients received active VNS after the ini-
tial 10-week evaluation period), the response rate
increased to 27% and remission rate was 16%.
168These
*Editor's note: see also the article by Eitan and Lerer (this issue, p 241) for a
detailed review of these techniques.Basic research
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1-year response and remission rates were better than
those in a medication management, observation-only
comparison group of similarly treatment-resistant
patients followed for a similar period of time (13%
response and 7% remission in the observation-only
group).
169 Longer-term response,remission,and relapse
data are not currently available for this group of patients.
Generally,VNS is safe,well-tolerated,and acceptable to
patients.The body of data, taken together in this very
refractory patient population, was sufficient to lead to
FDA to approve VNS for the treatment of pharmaco-
resistant depression.
The potential mechanism(s) of action of VNS are not
fully understood.The central projections of the vagus
nerve via the nucleus tractus solitarius innervate multi-
ple brain areas implicated in mood regulation,and func-
tional brain imaging studies have confirmed that VNS
alters activity of many of these cortical and subcortical
regions.
170VNS may affect function of GABA,
171,172 DA,
173
and NE,
174-177 though conflicting data have been
reported.
173These neurotransmitter system effects have
not been consistently associated with therapeutic
response.
171
Deep brain stimulation
Deep brain stimulation (DBS) involves a small electrical
stimulator implanted into a defined brain location which
typically provides chronic stimulation.Bilateral DBS of
the subthalamus or globus pallidus is an accepted treat-
ment for refractory Parkinson’s disease,
178,179 and can be
associated with significant mood changes in patients with
Parkinson’s disease.
180,181 A single open study reported
effects of bilateral high-frequency DBS of the white mat-
ter adjacent to the subgenual cingulate cortex in six
highly treatment-resistant depressed patients (five of
whom had failed ECT).
182 In this study, four of the six
patients showed an antidepressant response at the 6-
month study end point,with three in remission and the
fourth near remission.No significant adverse events were
noted.In this study,antidepressant response was associ-
ated with regional blood flow changes in brain regions
clearly implicated in the pathophysiology of depression
(dorsolateral prefrontal cortex,subgenual cingulate,peri-
genual anterior cingulate,hypothalamus,brain stem).
182
DBS appears to modulate function within discrete neural
networks,
183 although its actual mechanisms of action are
largely obscure. DBS may help restore normal neural
network function by decreasing function in abnormally
active “nodes,” by activating dormant compensatory
mechanisms, or by some combination of these two. If
DBS is confirmed to be an effective treatment for some
patients with depression, further investigation of its
mechanisms of action may greatly improve our under-
standing of the neurobiology of normal and abnormal
mood regulation.
Conclusion
Depression remains a prevalent and somewhat difficult-
to-treat disease despite decades of neurobiological
research and significant advances in the understanding
of its pathophysiology. Current and future research
efforts promise to further expand our knowledge of the
biological bases for depression and will likely contribute
a number of new antidepressant treatments. These
prospective treatments include several novel drugs tar-
geting neuromodulatory systems beyond the
monoamines and focal brain stimulation techniques
which directly target neural networks involved in depres-
sion.Over the next several years,we expect significant
advances to occur in our understanding and treatment of
depression. ❏
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Perspectivas futuras en la investigación de la
depresión
La depresión mayor es una enfermedad común,
incapacitante y a menudo difícil de tratar. Décadas
de investigación en la neurobiología y la terapéu-
tica de la depresión han permitido avanzar de
manera importante en nuestra capacidad para
manejar este trastorno. Sin embargo, persisten
diversos desafíos. Un número significativo de
pacientes depresivos no consiguen una remisión
completa, a pesar de optimizar los tratamientos.
Para los pacientes que logran la resolución de los
síntomas, la depresión se mantiene como una
enfermedad altamente recurrente y son comunes
los episodios repetidos. Finalmente, se conoce poco
acerca de cómo puede ser prevenida la depresión,
especialmente en sujetos con un alto riesgo. De
cara a estos desafíos es que actualmente se están
desarrollando varios excitantes esfuerzos de inves-
tigación que prometen expandir ampliamente
nuestro conocimiento sobre la etiología, la fisiopa-
tología y el tratamiento de la depresión. Esta revi-
sión destaca estas perspectivas futuras para la inves-
tigación en la depresión, con un foco específico en
las líneas de investigación que probablemente
generarán nuevas y más efectivas opciones de tra-
tamiento.    
Perspectives dans la recherche sur la 
dépression
La dépression majeure est une maladie répandue,
invalidante et souvent difficile à traiter. Des décen-
nies de recherche en neurobiologie et dans le trai-
tement de la dépression nous ont fait beaucoup
avancer dans la prise en charge de ce trouble. Il per-
siste néanmoins quelques défis à relever. Un
nombre non négligeable de patients déprimés
bénéficiant pourtant d’un traitement optimal, ne
guérissent pas complètement. Pour les patients
dont les symptômes disparaissent, la dépression
demeure à haut risque de récidive et les épisodes
répétés sont fréquents. En fin de compte, nous en
savons peu sur la prévention de la dépression sur-
tout chez les sujets dont le  risque est augmenté. En
réponse à ces questions, des efforts de recherche
passionnants sont actuellement en cours et vont
permettre d’enrichir notre connaissance de l’étio-
logie, de la physiopathologie et du traitement de
la dépression. Cette mise au point met en lumière
ces perspectives  pour la recherche sur la dépression
avec un intérêt particulier pour les voies qui débou-
cheront probablement sur de nouvelles possibilités
thérapeutiques, plus efficaces.
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